PDCD1 and melanoma: However, Heidelberger and colleagues performed a preclinical study with 77 patients with advanced melanoma, including 13 (19%) sarcopenic overweight patients treated with the anti-PD1 checkpoint inhibitors nivolumab or pembrolizumab in doses of 3 mg/kg every 2 weeks and 2 mg/kg-dose every 3 weeks, respectively.